Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sales Up 10.5%, Ordinary Profits Up 28.8%: Nichi-Iko
January 28, 2008
- New Sekisui Medical Aims at Sales of \50 Bil in FY2011
January 28, 2008
- Nippon Kayaku Aims at Sales of \10 Bil with Generic Anticancer Drugs
January 28, 2008
- MEDICAL DEVICE NEWS IN BRIEF
January 28, 2008
- Efforts of All Companies Required to Improve Reliability of Generics: JGPMA President Mr Sawai
January 28, 2008
- 24 "Advanced Healthcare Services" Recommended for Insurance Coverage
January 28, 2008
- Pharmacists Must Make Greater Efforts to Dispense Generics: JPA Vice president
January 28, 2008
- Chuikyo Subcommittee Resumes Discussions on Medical Fees
January 28, 2008
- MEXT Starts Full Discussions to Promote iPS Cell Research
January 28, 2008
- Gov't and Drug-Related Hepatitis Victims Agree on Settlement
January 28, 2008
- Korosho, MEXT, METI to Work Together to Promote iPS Cell Research
January 28, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 28, 2008
- Guidance to Promote Use of EDC Prepared by the JPMA
January 28, 2008
- TOPICS／PMDA Chief Executive Akira Miyajima Resigns
January 28, 2008
- Novartis to Step Back from Development of Vildagliptin in US
January 28, 2008
- Mundipharma to Focus on Pain and Cancer
January 28, 2008
- WG Proposes New Rule on Participation of Council Members with COI
January 28, 2008
- Takeda to Place Top Priority on Early Approval of SYR-322 and TAK-390MR: President Hasegawa
January 28, 2008
- REGULATORY NEWS IN BRIEF
January 28, 2008
- PMDA to Expand Review System for Generics, OTC Drugs: Chief Executive Miyajima
January 21, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…